schizofrenia
Conditions
Interventions
Intervention group:Agomelatine in combination with second-generation antipsychotics
control group:Second-generation antipsychotics alone
Sponsors
Jingzhou Mental Health Center
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) 18~65 years old, right-handed; (2) The main objective of this study was to explore the grouping treatment status of patients with negative symptoms of schizophrenia, so the following criteria were set when the samples were included: 7 points< 28 points on the PANSS positive symptoms subscale score = (all 7 items scored =4 points, i.e., none of them exceeded moderate); The PANSS Negative Symptom Scale has a score of =24 and at least 2 of the 3 core symptoms (emotional dullness, passivity/apathy, social withdrawal, and lack of spontaneity and fluency in conversation) = 4 or more; (3) The patient is aware of the study and signs the informed consent form,
Exclusion criteria
Exclusion criteria: (1) Patients with cerebral organic mental disorders or other severe mental disorders at the same time, or with severe positive symptoms or depressive symptoms (such as patients with strong suicidal ideation and recent history of suicide attempts); (2) Accompanied by mental retardation or other serious underlying diseases or physical diseases (such as auditory, visual impairments) that may affect the evaluation; (3) History of drug abuse or drug or alcohol dependence within the past 1 year; (4) Positive antibodies to hepatitis B virus, hepatitis C virus, anti-human immunodeficiency virus or elevated serum aminotransferases greater than or equal to the upper limit of normal; (5) the need for treatment with antidepressants other than agomelatine; (6) Those who have received MECT and rTMS treatment in the past month; (7) Allergy to agomelatine and its excipients or pregnant women, lactating women and women of childbearing age who do not take contraceptive measures. (8) Since low-dose amisulpride is widely accepted as one of the effective methods to improve negative symptoms of schizophrenia, we excluded this subset of patients who received amisulpride at the time of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scores on the PANSS scale;Scores on the SANS scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Scores on the CGI scale; | — |
Countries
China
Contacts
Public ContactZhang Xinfeng; Chen Zuowei
Jingzhou Mental Health Center
Outcome results
None listed